RxDoctor Payments Data

John Paik, MD

Internal Medicine · Douglas, GANPI 1619131299

Payments from drug & device makers

$9,262in general payments, 2019–2025

Across 403 payments — averaging $22.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • AstraZeneca$1K
  • GSK$815
  • Pfizer$510
  • Lilly USA, LLC$507
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$9,262100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,262 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$236,408
Medicare patients
636
Services billed
4,076

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$55,196
JanuviaSitagliptin Phosphate30$44,102
EliquisApixaban40$43,448
JardianceEmpagliflozin25$36,625
XareltoRivaroxaban19$25,671
FarxigaDapagliflozin Propanediol17$14,328
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,884
TradjentaLinagliptin17$9,586
ArexvyRsvpref3 Antigen/As01e/Pf26$7,901
InvokanaCanagliflozin11$6,326
ShingrixVaricella-Zoster Ge/As01b/Pf23$5,301
SynthroidLevothyroxine Sodium40$4,049
Novolog FlexpenInsulin Aspart16$3,967
Atorvastatin Calcium416$2,796
Levothyroxine Sodium233$2,484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,295$55,19642 claims
Boehringer IngelheimJardiance, Tradjenta$317$46,21142 claims
PfizerEliquis, Paxlovid$510$44,84056 claims
MerckJanuvia$153$44,10230 claims
Johnson & JohnsonXarelto, Invokana$325$31,99730 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$815$23,08663 claims
AstraZenecaFarxiga$1,015$14,32817 claims
AbbVieSynthroid$1,136$4,04940 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$2,484233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Douglas

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →